Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X:
“The VWF : GPIbM and VWF:RCo appear the most suitable assays for monitoring VWF activity in iTTP patients treatment with caplacizumab. The VWF:GPIbR have a limited ability to detect caplacizumab’s inhibition. The VWF:Ab assay is unsuitable for this purpose ”
Title: Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction.
Authors: Paola Colpani, Luciano Baronciani, Ilaria Mancini, Cristina Novembrino, Anna Lecchi, Giovanna Cozzi, Pasqualina De Leo, Massimo Boscolo Anzoletti, Silvia La Marca, Marco Boscarino, Maria Teresa Pagliari, Andrea Artoni, Flora Peyvandi
Read the full article here.
Stay updated with Hemostasis Today.
-
Dec 12, 2025, 10:17Alyssa George on Clinical and Economic Impact of a Eptacog Beta
-
Dec 12, 2025, 09:53Ivan Budnik Awarded AHA Postdoctoral Fellowship! Aiming to Improve DVT Long-term Outcomes
-
Dec 12, 2025, 09:34Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
-
Dec 12, 2025, 09:22Matteo Foschi Presents The New Expert Guidance on Minor Ischemic Stroke
-
Dec 12, 2025, 07:00Umberto Pensato on Cancer and Stroke
-
Dec 12, 2025, 06:48Steve Tuplin on A New Era in Haemophilia A Care: Reflections from ASH25
-
Dec 12, 2025, 06:30Anirban Sen Gupta on Synthetic Platelets
-
Dec 12, 2025, 05:59Gaetan Duport: A New Legislation for Medicines in Europe
-
Dec 11, 2025, 23:31Gregory Piazza on Insights for COVID19 Patients in the CORONA-VTE Network Study